Approval · Notice of Compliance 19972 · 2017
ACTEMRA: Notice of Compliance 19972
Issued October 27, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19972
- Date
- October 27, 2017
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- For the treatment of giant cell arteritis (gca) in adult patients
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTEMRA | Not yet assigned | — |
Medicinal ingredients
- TOCILIZUMAB 162 MG per 0.9ML